Financial Highlights for SI-BONE in 2024
SI-BONE, Inc. (NASDAQ: SIBN), renowned for its advancements in medical technology for sacropelvic disorders, has recently shared preliminary financial results that reflect its commitment to innovation and growth. With an impressive estimated revenue between $48.8 to $49.0 million for the fourth quarter of 2024, this signals a significant 26% increase compared to the previous year.
A Deep Dive into Fourth Quarter Achievements
The fourth quarter demonstrated remarkable success for SI-BONE. The company experienced a 28% growth in U.S. revenue, amounting to approximately $46.7 to $46.9 million. This growth not only reflects the rising demand for their unique pelvic health solutions but also highlights the effectiveness of their outreach in the U.S. medical community. SI-BONE ended the quarter with about 1,390 active physicians participating in their network, a 23% increase from the prior year, indicating a robust expansion in practitioner engagement.
Profits and Cash Position
Additionally, SI-BONE’s cash and marketable securities stood around $150 million, with minimal net cash usage of about $0.8 million during the quarter. This solid cash position provides the company with a strong foundation for future growth and investment in innovation.
Overview of Full Year 2024 Performance
As for the full fiscal year 2024, SI-BONE reported total worldwide revenue between $167.0 and $167.1 million, reflecting a steady growth rate of around 20%. The U.S. market also contributed significantly to this growth, with reported revenues estimated between $158.2 and $158.4 million, representing an increase of approximately 21%. These figures illustrate the effectiveness of SI-BONE's strategies and the burgeoning demand for its innovative medical devices.
Future Prospects
Looking ahead, SI-BONE plans to disclose detailed financial results for the fourth quarter and full year during an upcoming earnings call. Investors and stakeholders are eagerly anticipating further insights into the company’s operations and strategic direction. The management emphasizes that the preliminary figures are subject to adjustment as final audits are completed.
About SI-BONE and Its Innovations
Founded in 2009, SI-BONE has emerged as a leader in the development of advanced technologies for treating sacropelvic disorders. With a strong emphasis on minimally invasive procedures, the company has supported over 4,300 physicians and conducted more than 115,000 surgical procedures worldwide. Backed by a robust clinical database, including randomized controlled trials and over 160 peer-reviewed publications, SI-BONE continues to expand its influence in adjacent markets, including adult deformity correction, pelvic trauma management, and sacropelvic fixation.
Commitment to Safety and Effectiveness
It's important for patients and healthcare providers to understand the risks and benefits associated with SI-BONE’s technologies. The company's commitment to safety and efficacy underpins its operations, ensuring that all innovations cater to improved patient outcomes.
Frequently Asked Questions
What is the expected revenue growth for SI-BONE in 2024?
SI-BONE anticipates a significant revenue growth, with a projected fourth quarter revenue increase of around 26%.
How many active physicians are involved with SI-BONE in the U.S.?
As of the end of the fourth quarter, there are approximately 1,390 active physicians in the U.S. utilizing SI-BONE’s products.
What are SI-BONE's cash reserves like currently?
The company reported cash and marketable securities amounting to about $150 million, indicating strong financial health.
What is SI-BONE's primary focus as a company?
SI-BONE focuses on developing minimally invasive technologies for surgical treatments, specifically targeting sacropelvic disorders.
When will SI-BONE provide detailed financial results?
SI-BONE is expected to reveal its detailed financial results for the fourth quarter and full year during its earnings call scheduled for late February 2025.
